drugset / Trial / NCT04406610
CAR-T Cell Immunotherapy for GD2 Positive Glioma Patients
RandomizedParallel-groupSingle-blindTreatment
Summary
The purpose of this study is to evaluate the safety and effectiveness of CAR-T cell immunotherapy in treating with GD2 positive glioma patients.
Timeline
- Start
- 2015-09-01
- Primary completion
- 2016-08-15
- Completion
- 2016-10-15
Outcome
Outcome not reported
Stopped: “Project terminated due to revision of local regulations”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | GD2 CAR-T immunotherapy | Cell therapy | — | Intravenous |